Targeting tumor-associated macrophages with nanocarrier-based treatment for breast cancer: A step toward developing innovative anti-cancer therapeutics

doi:10.1016/j.heliyon.2024.e37217

Review

. 2024 Aug 30;10(18):e37217.

doi: 10.1016/j.heliyon.2024.e37217. eCollection 2024 Sep 30.

Targeting tumor-associated macrophages with nanocarrier-based treatment for breast cancer: A step toward developing innovative anti-cancer therapeutics

Ghazala Muteeb¹, Doaa S R Khafaga², Manar T El-Morsy³, Mohd Farhan^{4

5}, Mohammad Aatif⁶, Mohamed Hosney⁷

Affiliations

¹ Department of Nursing, College of Applied Medical Sciences, King Faisal University, Al-Ahsa, 31982, Saudi Arabia.
² Health Sector, Faculty of Science, Galala University, New Galala City, 43511, Suez, Egypt.
³ Biotechnology Department, Faculty of Science, Cairo University, 12613, Giza, Egypt.
⁴ Department of Chemistry, College of Science, King Faisal University, Al Ahsa, 31982, Saudi Arabia.
⁵ Department of Basic Sciences, Preparatory Year Deanship, King Faisal University, Al Ahsa, 31982, Saudi Arabia.
⁶ Department of Public Health, College of Applied Medical Sciences, King Faisal University, Al-Ahsa, 31982, Saudi Arabia.
⁷ Zoology Department, Faculty of Science, Cairo University, 12613, Giza, Egypt.

PMID: 39309874
PMCID: PMC11415663
DOI: 10.1016/j.heliyon.2024.e37217

Review

Targeting tumor-associated macrophages with nanocarrier-based treatment for breast cancer: A step toward developing innovative anti-cancer therapeutics

Ghazala Muteeb et al. Heliyon. 2024.

. 2024 Aug 30;10(18):e37217.

doi: 10.1016/j.heliyon.2024.e37217. eCollection 2024 Sep 30.

Authors

Ghazala Muteeb¹, Doaa S R Khafaga², Manar T El-Morsy³, Mohd Farhan^{4

5}, Mohammad Aatif⁶, Mohamed Hosney⁷

Affiliations

¹ Department of Nursing, College of Applied Medical Sciences, King Faisal University, Al-Ahsa, 31982, Saudi Arabia.
² Health Sector, Faculty of Science, Galala University, New Galala City, 43511, Suez, Egypt.
³ Biotechnology Department, Faculty of Science, Cairo University, 12613, Giza, Egypt.
⁴ Department of Chemistry, College of Science, King Faisal University, Al Ahsa, 31982, Saudi Arabia.
⁵ Department of Basic Sciences, Preparatory Year Deanship, King Faisal University, Al Ahsa, 31982, Saudi Arabia.
⁶ Department of Public Health, College of Applied Medical Sciences, King Faisal University, Al-Ahsa, 31982, Saudi Arabia.
⁷ Zoology Department, Faculty of Science, Cairo University, 12613, Giza, Egypt.

PMID: 39309874
PMCID: PMC11415663
DOI: 10.1016/j.heliyon.2024.e37217

Abstract

Tumor-associated macrophages (TAMs) promote tumor advancement in many ways, such as inducing angiogenesis and the formation of new blood vessels that provide tumors with nourishment and oxygen. TAMs also facilitate tumor invasion and metastasis by secreting enzymes that degrade the extracellular matrix and generating pro-inflammatory cytokines that enhance the migration of tumor cells. TAMs also have a role in inhibiting the immune response against malignancies. To accomplish this, they release immunosuppressive cytokines such as IL-10, and TAMs can hinder the function of T cells and natural killer cells, which play crucial roles in the immune system's ability to combat cancer. The role of TAMs in breast cancer advancement is a complex and dynamic field of research. Therefore, TAMs are a highly favorable focus for innovative breast cancer treatments. This review presents an extensive overview of the correlation between TAMs and breast cancer development as well as its role in the tumor microenvironment (TME) shedding light on their impact on tumor advancement and immune evasion mechanisms. Notably, our study provides an innovative approach to employing nanomedicine approaches for targeted TAM therapy in breast cancer, providing an in-depth overview of recent advances in this emerging field.

Keywords: Angiogenesis; Breast cancer progression; Immunosuppression; M1; M2; Metastasis; Tumor associated macrophages.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

**Fig. 1**
Activation of tissue macrophage. Microbes cytokine (IFNγ), fibroblast growth factors (FGF), platelet derived growth factor (PDGF)and Interleukin 4 (IL-4).

**Fig. 2**
The role of tumor-associated macrophages (TAM) in cancer cell progression.

**Fig. 3**
Several applications of nanoparticles in biomedical field.

**Fig. 4**
Different types of nanoparticles (NPs) are used in drug delivery systems.

See this image and copyright information in PMC

References

1. Huang Xinqun, Cao Jingsong, Zu X. Tumor‐associated macrophages: an important player in breast cancer progression. Thoracic Cancer. 2022;13:269–276. doi: 10.1111/1759-7714.14268. - DOI - PMC - PubMed
1. Chen F., Chen J., Yang L., Liu J., Zhang X., Zhang Y., Tu Q., Yin D., Lin D., Wong P.-P., Huang D., Xing Y., Zhao J., Li M., Liu Q., Su F., Su S., Song E. Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. Nat. Cell Biol. 2019;21:498–510. doi: 10.1038/s41556-019-0299-0. - DOI - PubMed
1. Wei X., Wang J., Liang M., Song M. Development of functional nanomedicines for tumor associated macrophages-focused cancer immunotherapy. Theranostics. 2022;12:7821–7852. doi: 10.7150/thno.78572. - DOI - PMC - PubMed
1. Zhang Y., Chen Y., Li J., Zhu X., Liu Y., Wang X., Wang H., Yao Y., Gao Y., Chen Z. Development of toll-like receptor agonist-loaded nanoparticles as precision immunotherapy for reprogramming tumor-associated macrophages. ACS Appl. Mater. Interfaces. 2021;13:24442–24452. doi: 10.1021/acsami.1c01453. - DOI - PubMed
1. Clark N.M., Bos P.D. In: Cancer Immunosurveillance. López-Soto A., Folgueras A.R., editors. Springer New York; New York, NY: 2019. Tumor-associated macrophage isolation and in vivo analysis of their tumor-promoting activity; pp. 151–160. - DOI - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- PubMed Central

[1] Huang Xinqun, Cao Jingsong, Zu X. Tumor‐associated macrophages: an important player in breast cancer progression. Thoracic Cancer. 2022;13:269–276. doi: 10.1111/1759-7714.14268. - DOI - PMC - PubMed

[2] Huang Xinqun, Cao Jingsong, Zu X. Tumor‐associated macrophages: an important player in breast cancer progression. Thoracic Cancer. 2022;13:269–276. doi: 10.1111/1759-7714.14268. - DOI - PMC - PubMed

[3] Chen F., Chen J., Yang L., Liu J., Zhang X., Zhang Y., Tu Q., Yin D., Lin D., Wong P.-P., Huang D., Xing Y., Zhao J., Li M., Liu Q., Su F., Su S., Song E. Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. Nat. Cell Biol. 2019;21:498–510. doi: 10.1038/s41556-019-0299-0. - DOI - PubMed

[4] Chen F., Chen J., Yang L., Liu J., Zhang X., Zhang Y., Tu Q., Yin D., Lin D., Wong P.-P., Huang D., Xing Y., Zhao J., Li M., Liu Q., Su F., Su S., Song E. Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. Nat. Cell Biol. 2019;21:498–510. doi: 10.1038/s41556-019-0299-0. - DOI - PubMed

[5] Wei X., Wang J., Liang M., Song M. Development of functional nanomedicines for tumor associated macrophages-focused cancer immunotherapy. Theranostics. 2022;12:7821–7852. doi: 10.7150/thno.78572. - DOI - PMC - PubMed

[6] Wei X., Wang J., Liang M., Song M. Development of functional nanomedicines for tumor associated macrophages-focused cancer immunotherapy. Theranostics. 2022;12:7821–7852. doi: 10.7150/thno.78572. - DOI - PMC - PubMed

[7] Zhang Y., Chen Y., Li J., Zhu X., Liu Y., Wang X., Wang H., Yao Y., Gao Y., Chen Z. Development of toll-like receptor agonist-loaded nanoparticles as precision immunotherapy for reprogramming tumor-associated macrophages. ACS Appl. Mater. Interfaces. 2021;13:24442–24452. doi: 10.1021/acsami.1c01453. - DOI - PubMed

[8] Zhang Y., Chen Y., Li J., Zhu X., Liu Y., Wang X., Wang H., Yao Y., Gao Y., Chen Z. Development of toll-like receptor agonist-loaded nanoparticles as precision immunotherapy for reprogramming tumor-associated macrophages. ACS Appl. Mater. Interfaces. 2021;13:24442–24452. doi: 10.1021/acsami.1c01453. - DOI - PubMed

[9] Clark N.M., Bos P.D. In: Cancer Immunosurveillance. López-Soto A., Folgueras A.R., editors. Springer New York; New York, NY: 2019. Tumor-associated macrophage isolation and in vivo analysis of their tumor-promoting activity; pp. 151–160. - DOI - PubMed

[10] Clark N.M., Bos P.D. In: Cancer Immunosurveillance. López-Soto A., Folgueras A.R., editors. Springer New York; New York, NY: 2019. Tumor-associated macrophage isolation and in vivo analysis of their tumor-promoting activity; pp. 151–160. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Targeting tumor-associated macrophages with nanocarrier-based treatment for breast cancer: A step toward developing innovative anti-cancer therapeutics

Affiliations

Targeting tumor-associated macrophages with nanocarrier-based treatment for breast cancer: A step toward developing innovative anti-cancer therapeutics

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

References

Publication types

LinkOut - more resources

Full Text Sources

Abstract

Conflict of interest statement

Figures

Similar articles

References

Publication types

Related information

LinkOut - more resources

Full Text Sources